NL
DE
Rob Collin (Dept. of Human Genetics) and Carel Hoyng (Dept. of Ophthalmology), theme Sensory disorders, have received a prestigious award from the Translational Research Acceleration Program of the Foundation Fighting Blindness USA.
This program is dedicated to further translate innovative therapeutic proof-of-concept to patients with retinal disease. With this three-year award, Rob and Carel, together with their team of collaborators, aim to bring antisense oligonucleotide-based splicing modulation therapy for patients with Stargardt disease up to the phase of clinical testing.
Related news items
Surprisingly dominant cause underlying type I congenital defect of glycosylation
21 October 2021 Alex Garanto, Melissa Bärenfänger, Mirian Janssen, and Dirk Lefeber published a new study, identifying a surprisingly dominant genetic cause underlying type I congenital defect of glycosylation with neuromusculoskeletal phenotypes. read more
Treatment of brain diseases at risk if neuroscientists can no longer conduct their research
5 August 2021 In order to treat brain diseases such as depression, Alzheimer's or ADHD, more research into the brain is needed. read more
Retina-on-chip modeling and treating eye diseases in a dish
10 June 2021Alex Garanto, together with Anneke den Hollander and Andries van der Meer (UTwente) have received 1,17M€ to develop a retina-on-chip model to improve our understanding in eye diseases and to develop treatments against them.
read more
Innovative therapy developed for the future treatment of hereditary (deaf)blindness
26 May 2021 Researchers from the department of Otorhinolaryngology, headed by Erwin van Wijk, developed a novel therapeutic strategy to halt the progression or to prevent vision loss in patients as a consequence of USH2A exon 13 mutations. read more
Rob Collin appointed Professor of Molecular therapy for inherited retinal diseases
3 February 2021 Effective 16 January 2021, molecular geneticist Rob Collin has been appointed Professor of 'Molecular Therapy for Inherited Retinal Diseases' at Radboudumc Radboud University. read more
